Download PDF

1. Company Snapshot

1.a. Company Description

Paragon 28, Inc.designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally.It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems.


The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis.In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot.Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application.


Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments.The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors.Paragon 28, Inc.


was founded in 2010 and is headquartered in Englewood, Colorado.

Show Full description

1.b. Last Insights on FNA

Here is a 90-word analysis of the positive drivers behind Paragon 28, Inc.'s recent stock performance: The acquisition by Zimmer Biomet Holdings, Inc. for $13.00 per share in cash, along with a non-tradeable contingent value right entitling shareholders to receive up to $1.00 per share in cash if certain revenue milestones are achieved, has driven optimism. Multiple law firms, including Halper Sadeh LLC, Bronstein, Gewirtz & Grossman, LLC, are investigating the sale, suggesting potential upside for shareholders. Wall Street analysts predict a 39.67% upside, driven by an upward trend in earnings estimate revisions, hinting at a potential near-term upside.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Investors to Reach Out

Jun -17

Source: accessnewswire.com

Card image cap

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Stockholders to Reach Out

Jun -15

Source: accessnewswire.com

Card image cap

Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Stockholders to Connect

Jun -12

Source: accessnewswire.com

Card image cap

Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun -10

Source: accessnewswire.com

Card image cap

Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Shareholders to Inquire about Securities Investigation

Jun -08

Source: accessnewswire.com

Card image cap

Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Shareholders to Connect

Jun -05

Source: accessnewswire.com

Card image cap

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Shareholders to Reach Out

Jun -03

Source: accessnewswire.com

Card image cap

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Shareholders to Learn More About the Investigation

Jun -01

Source: accessnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Medical Devices

Expected Growth: 8.5%

Paragon 28, Inc.'s medical devices segment growth of 8.5% is driven by increasing demand for minimally invasive surgical procedures, expansion into new markets, and innovative product launches. Additionally, the company's focus on orthopedic and podiatric solutions, as well as strategic partnerships, contribute to its growth momentum.

7. Detailed Products

AquaLance

AquaLance is a line of innovative, minimally invasive, and disposable instruments designed for foot and ankle procedures.

Gorilla

Gorilla is a comprehensive system of implants and instruments designed for hindfoot and ankle reconstruction.

Phantom

Phantom is a line of titanium and stainless steel implants designed for foot and ankle reconstruction.

Swift

Swift is a line of instruments and implants designed for minimally invasive foot and ankle procedures.

Pulse

Pulse is a line of instruments and implants designed for electrophysiology and nerve stimulation procedures.

8. Paragon 28, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Paragon 28, Inc. is medium due to the presence of alternative products and services in the medical device industry.

Bargaining Power Of Customers

The bargaining power of customers for Paragon 28, Inc. is low due to the company's strong brand reputation and customer loyalty.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Paragon 28, Inc. is medium due to the presence of multiple suppliers in the market.

Threat Of New Entrants

The threat of new entrants for Paragon 28, Inc. is high due to the growing demand for medical devices and the ease of entry into the market.

Intensity Of Rivalry

The intensity of rivalry for Paragon 28, Inc. is high due to the presence of established competitors in the medical device industry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 38.44%
Debt Cost 4.59%
Equity Weight 61.56%
Equity Cost 9.53%
WACC 7.63%
Leverage 62.44%

11. Quality Control: Paragon 28, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Alphatec Holdings

A-Score: 4.5/10

Value: 6.6

Growth: 5.4

Quality: 2.9

Yield: 0.0

Momentum: 10.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Paragon 28

A-Score: 4.5/10

Value: 6.6

Growth: 1.7

Quality: 4.6

Yield: 0.0

Momentum: 10.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Senseonics Holdings

A-Score: 3.7/10

Value: 6.0

Growth: 5.6

Quality: 2.5

Yield: 0.0

Momentum: 7.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Inogen

A-Score: 3.6/10

Value: 8.8

Growth: 1.4

Quality: 4.5

Yield: 0.0

Momentum: 4.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Sight Sciences

A-Score: 3.1/10

Value: 7.0

Growth: 5.8

Quality: 4.1

Yield: 0.0

Momentum: 1.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Cutera

A-Score: 2.8/10

Value: 10.0

Growth: 1.6

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

13.09$

Current Price

13.09$

Potential

-0.00%

Expected Cash-Flows